A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Administered at a High, Mid and Low Titre as a 3 Dose Neonate Schedule or Administered at a High Titre as a 3 Dose Infant Schedule.
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2018
At a glance
- Drugs Rotavirus vaccine (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- 24 Jun 2018 Status changed from not yet recruiting to recruiting.
- 04 Apr 2018 New trial record